HCG for Men

Human chorionic gonadotropin is a placental hormone, and the reason it matters for men has nothing to do with pregnancy. The prescribing information states that its action is virtually identical to pituitary luteinizing hormone, stimulating the interstitial cells, or Leydig cells, of the testis to produce androgens. Injected testosterone raises the level in your blood while shutting off the pituitary signal that keeps the testicle working. hCG substitutes for that signal, which is the one thing testosterone itself can never do.

Clear one thing up before anything else. The hCG diet is not this drug used differently, it is a separate product category. FDA and FTC issued seven joint warning letters to firms selling over-the-counter homeopathic hCG weight-loss drops, pellets, and sprays, and FDA states that all drug products claiming to include homeopathic hCG are illegally marketed.

The prescription label itself opens in capitals with a statement that hCG has no known effect on fat mobilization, appetite, or body fat distribution.

The AUA's 2024 testosterone deficiency guideline puts hCG activity as virtually identical to LH, with a peak around 12 hours and a half-life of roughly two days. That long tail is why dosing is usually every other day rather than daily. It also explains the drug's split personality. Used at a low dose beside testosterone it is a maintenance tool for the testicle, and used at a higher dose on its own it is a way to make your own testosterone instead of importing it.

The number underneath every hCG-with-testosterone protocol comes from one small randomized study. In 29 normal men given 200 mg testosterone enanthate weekly plus saline, intratesticular testosterone fell 94% within three weeks. The same trial added hCG at three doses. At 500 IU every other day intratesticular testosterone finished 26% above baseline, at 250 IU it sat 7% below, and at 125 IU 25% below. That dose-response curve is the entire origin of the 250 to 500 IU every-other-day adjunct regimen you will see quoted everywhere.

A retrospective review of 26 hypogonadal men on testosterone plus 500 IU hCG every other day reported serum testosterone rising from 207 to 1,056 ng/dL with no change in semen parameters and no man becoming azoospermic over a mean 6.2 months. Nine of the 26 went on to contribute to a pregnancy. That is a chart review, not a trial. The AUA describes the underlying intratesticular finding as coming from a single small study, and it is worth holding both facts at once: the signal is consistent and mechanistically sensible, and the evidence base is thin.

Restarting after testosterone has its own literature and it is stronger on numbers. Among 49 men azoospermic or severely oligospermic on testosterone, stopping it and adding 3,000 units of hCG subcutaneously every other day with a SERM, anastrozole, or recombinant FSH returned or improved sperm in 95.9%, averaging 4.6 months. In a separate group of 66 men infertile after testosterone use, 70% reached a total motile count above 5 million, with 64.8% of the azoospermic subgroup recovering by 12 months against 91.7% of those who still had rare sperm at baseline.

The approved indications are prepubertal cryptorchidism not due to anatomical obstruction, selected cases of hypogonadotropic hypogonadism in males, meaning hypogonadism secondary to a pituitary deficiency, and induction of ovulation in the anovulatory infertile woman. That is the whole list. The AUA notes that among the fertility-sparing hormone options, only hCG holds an FDA approval for use in males. Every regimen you will read about running hCG next to testosterone sits outside that label, which does not make it wrong, only unapproved.

Two situations account for most real prescribing. The first is protecting testicular function while you are on testosterone and want to keep the fertility door open. The second is restarting your own production after you come off. Both assume someone has already worked out why your LH is low. Low LH with low testosterone points upstream to the pituitary or hypothalamus, which is exactly where an LH analog helps. High LH with low testosterone points at the testicle itself, and hCG has far less to offer there.

It is a poor fit if you have had no hormone workup, if your goal is weight loss, or if a contraindication applies. The label rules it out in precocious puberty, prostatic carcinoma or other androgen-dependent neoplasm, and prior allergic reaction to hCG. It also flags that androgen-driven fluid retention makes caution reasonable if you have cardiac or renal disease, epilepsy, migraine, or asthma.

A licensed clinician decides suitability. Nothing on this page is medical advice.

The closest comparison is a SERM such as clomiphene, which has its own page on this site. The mechanical difference decides most of the rest: clomiphene blocks estrogen feedback so your own pituitary releases more LH, while hCG bypasses the pituitary and acts as LH. That makes hCG the option that still works when the pituitary is the part that is not responding, and it makes clomiphene the option that comes as a tablet rather than a syringe.

A randomized comparison in 282 hypogonadal men who wanted to preserve fertility tested clomiphene 50 mg, hCG 5,000 IU twice weekly, and the two combined, and found all three raised testosterone with no significant difference between the groups, while the combination scored significantly better on a symptom questionnaire. The AUA rates this whole class as a conditional recommendation at evidence grade C and calls the quantity and quality of studies in males limited. In practice, injection tolerance, cost, and whether your pituitary can respond decide it more often than potency does.

On-label, hypogonadotropic hypogonadism is treated with 500 to 1,000 USP units three times a week for three weeks followed by the same dose twice a week for three weeks, or alternatively 4,000 USP units three times weekly for six to nine months before dropping to 2,000 units three times weekly. Read that twice, because neither schedule is the one discussed alongside testosterone therapy. The approved regimen is monotherapy at a dose meant to replace a missing LH signal outright, rather than a low-dose add-on.

For men on testosterone who want to preserve fertility, the AUA describes hCG at 250 IU or 500 IU every other day given concurrently, while its own dosing table gives a wider 500 to 4,000 IU two to three times per week. Restart protocols run higher again: the 49-man recovery series used 3,000 units every other day. That spread is not sloppiness, it reflects how little trial data sits under any single number, and it is why a prescriber should be able to explain the dose they chose.

Route is where label and practice openly diverge, and you should know that going in. The Pregnyl label says for intramuscular use only, and the Novarel label carries the same restriction. The AUA's dosing table lists hCG as subcutaneous or intramuscular, and the restart series injected subcutaneously. Subcutaneous dosing is off-label, common, and easier to self-administer with an insulin syringe. Reconstituted vials need refrigeration and complete use within 60 days.

The label lists headache, irritability, restlessness, depression, fatigue, edema, precocious puberty, gynecomastia, and pain at the site of injection. Gynecomastia is the one that sends men searching for explanations, and the mechanism is not mysterious. hCG drives testosterone production inside the testis, the testis also converts testosterone to estradiol through aromatase, so a stronger LH signal lifts both hormones together. Higher doses and tighter dosing intervals push harder on that same pathway.

What that implies is practical: estradiol is worth measuring rather than guessing at, particularly in the first couple of months. Breast tenderness, nipple sensitivity, or visible tissue change is a reason to contact whoever prescribed it instead of self-adjusting. The AUA lists aromatase inhibitors in the same conditional, grade C recommendation as hCG for men who want to maintain fertility, so lowering the hCG dose and adding an aromatase inhibitor are both recognized responses. Which one applies to you is a clinical judgment.

Two label details are easy to miss and both matter for monitoring. hCG interferes with the radioimmunoassay measurement of gonadotropins, particularly LH, so a gonadotropin result drawn while you are taking it can mislead anyone reading the chart. Mention it to any clinician ordering hormone labs. The label also warns that androgen-driven fluid retention deserves caution in cardiac or renal disease, epilepsy, migraine, and asthma.

hCG is prescription-only and exists only as an injection, which rules out every drop, pellet, and spray sold as hCG online. FDA states that FDA-approved hCG products are available only in injection form and require a prescription from a licensed medical professional. A telehealth visit is a legitimate route to that prescription, but the intake should include hormone labs. Any service willing to prescribe it without measuring LH, FSH, and total testosterone is skipping the step the drug depends on.

The supply picture changed permanently in 2020, and the change is often described as contested when it is not. Under the BPCI Act, on March 23, 2020 approved applications for certain protein products became biologics licenses, and FDA notified compounders that human chorionic gonadotropin was one of four affected bulk substances that would no longer be eligible for the compounding exemptions under sections 503A and 503B. FDA's interim policy on compounding with bulk drug substances, published January 2025, repeats that products approved under a biologics license application are not eligible and will not be considered for the 503A bulks list. So compounded hCG did not become restricted, it lost its legal footing and has not regained it. The proof sits on the label itself: the generic vial now carries biologics license number BLA 017067 and a US license number where it once carried an NDA. What remains available are the licensed finished products, the Fresenius Kabi generic vial, Pregnyl from Organon, and Novarel from Ferring. If a service offers you a compounded hCG preparation, ask what it actually is.

Concurrent use is the more common pattern. Testosterone continues, and a low hCG dose runs beside it to keep the intratesticular signal alive. The AUA frames it in those terms, saying clinicians may offer hCG at 250 or 500 IU every other day concurrent with exogenous testosterone, while noting the supporting evidence is a single small study.

Two things it is not: a promise that fertility will be preserved, and a form of contraception. Semen analysis is the only way to know where you actually stand.

Restarting is a different job with different drugs. Testosterone stops, and hCG is usually combined with a SERM, sometimes with an aromatase inhibitor or recombinant FSH, to push both halves of the axis at once. The 49-man series reporting 95.9% return or improvement in sperm used exactly that kind of combination, with an average time to recovery of 4.6 months. Nobody in that literature saw a fast answer, so a protocol that promises one is worth questioning.

Worth knowing before you assume a restart drug is required: recovery frequently happens on its own. A pooled analysis of 30 hormonal male contraceptive studies covering 1,549 men found 67% returned to above 20 million sperm per mL within 6 months, 90% within 12 months, and 100% by 24 months. Those were healthy men on controlled study regimens rather than long-term testosterone therapy, so it is a floor rather than a forecast, but it is the baseline any added drug has to improve on.

Start with the public prices that are not marketing numbers, and note there is more than one. In the file published on 2 September 2026, Medicaid's National Average Drug Acquisition Cost lists the unbranded 10,000-unit chorionic gonadotropin vial at $251.58, Pregnyl at $171.53 for the same 10,000 units, and Novarel at $171.81 for a 5,000-unit vial. NADAC is the cost pharmacies pay to acquire a drug, surveyed by CMS, and it is not a retail price. Every one of those rows is flagged brand rather than generic for rate setting, which follows from these being licensed biologics with no true generic behind them. The spread is the part worth reading: the unbranded vial is the most expensive 10,000-unit option on the file, not the cheapest, and Novarel at half the units for the same money is dearer again per unit.

The arithmetic matters more than the headline figure. A 10,000-unit vial is 20 doses at 500 IU or 40 doses at 250 IU. At 500 IU every other day that is about one vial per 40 days, which fits inside the label's 60-day limit after reconstitution. At 250 IU every other day it does not, so part of the vial expires unused and your real cost per dose rises rather than halving.

Acquisition cost lands between about $8.60 and $12.60 per 500 IU dose, depending which vial you are dispensed.

What you pay is a different number. Pharmacies and telehealth services price above acquisition cost, and the visit, the lab panel, syringes, and bacteriostatic water are usually separate line items. Insurance behaves inconsistently because the common uses are off-label, and coverage is more plausible when the documented diagnosis is hypogonadotropic hypogonadism, the indication that is on the label. Ask for an all-in monthly figure including labs before you commit to any plan.

Judge a service by its workup rather than its landing page. hCG only makes sense once someone knows whether your pituitary signal is low, normal, or high, which means LH and FSH measured alongside total testosterone, and usually estradiol. A questionnaire-only intake that arrives at an injectable hormone has skipped the test that decides whether this drug can do anything for you. Ask outright whether the proposed use is on-label, and ask what product you will actually receive, since the compounding pathway closed in 2020 and a licensed vial is the answer you want.

Then ask about follow-up, because that is where cheap plans get expensive. Find out who reads your labs, how often they are drawn, and what result would trigger a dose change. Whether hCG fits your situation is a prescribing decision, and none of this is medical advice.

Ask what happens to the protocol if you decide to try to conceive, since the guideline position is that testosterone should not be prescribed to men currently trying to conceive.